PTA BALLOON CATHETER MARKET ANALYSIS

PTA Balloon Catheter MarketSize and Trends

PTA stands for ‘percutaneous transluminal angioplasty’. PTA balloon catheter has an inflatable balloon at its tip, which is used during a minimally invasive catheterization procedure. The deflated balloon is positioned at the narrowed space and inflated for the short period of time and deflated again to be removed. PTA balloons come in various sizes, lengths, and shapes, depending on the anatomy they are intended to treat. PTA balloon catheters can be used in two ways for the treatment of peripheral vascular lesions. One way is to expand the lumen of an obstructed blood vessel. This method is referred to as the ‘plain-old balloon angioplasty’ (POBA). The second use is for expanding stents for the treatment of vascular blockages.

Global PTA balloon catheter market is estimated to be valued at US$ 1,556.0 million in 2022 and is expected to exhibit a CAGR of 7.1% during the forecast period (2022-2030).

Figure 1. Global PTA Balloon Catheter Market Share (%), by Material Type, 2022

Increasing preference of polyurethane due to it compatibility is expected to propel growth of the global PTA balloon catheter market over the forecast period.

Polyurethane is considered as the desirable material used for the manufacturing of balloon catheters due to the various advantages provided by it such as

• Good tensile strength,
• Hemocompatibility and
• Biocompatibility

There are several advantages offered by polyurethane balloon such as superior characteristics, including relatively high burst strength and good flexibility, which are expected to drive the segment growth over the forecast period.

Figure 2. Global PTA Balloon Catheter Market Share (%), by Region, 2022

Increasing number of inorganic strategies such as product launch and product approval from the U.S. FDA (Food and Drug Administration) by the market players in North America is expected to boost the global PTA balloon catheter market growth over the forecast period.

Increasing number of inorganic strategies such as product launch by the market players in North America is expected to boost the global PTA balloon catheter market growth over the forecast period. For instance, in August 2019, B. Braun Interventional Systems Inc., a medical device company, announced Breakthrough Device Designation for the SeQuent Please ReX drug-coated PTCA  (percutaneous transluminal coronary angioplasty) balloon catheter for the treatment of coronary in-stent restenosis (ISR) from the U.S. Food and Drug Administration (FDA).

For instance, on June 2, 2022, Cardio Flow, Inc., a medical device company and developer of minimally invasive peripheral vascular devices to treat peripheral artery disease (PAD), announced that it had received U.S. Food and Drug Administration (FDA) clearance for the company’s FreedomFlow Peripheral Guidewire. The FreedomFlow guidewire is stainless steel core-to-tip design with a fixed distal-spring coil which provide support for diagnostic and therapeutic devices used in treating plaque blockages in arteries both above and below the knee.